Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Jul 27, 2013; 5(7): 372-378
Published online Jul 27, 2013. doi: 10.4254/wjh.v5.i7.372
Published online Jul 27, 2013. doi: 10.4254/wjh.v5.i7.372
In vivo assessment of intratumoral aspirin injection to treat hepatic tumors
Rogério Saad-Hossne, Fábio Vieira Teixeira, Rafael Denadai, Division of Coloproctology, Department of Surgery, Botucatu Medical School, University of the State of São Paulo, 18618-000 Botucatu-SP, Brazil
Author contributions: Saad-Hossne R and Denadai R conceived and designed the study, acquired the data, and performed data analysis and interpretation; Saad-Hossne R, Teixeira FV and Denadai R wrote the manuscript; Saad-Hossne R performed the statistical analysis, provided equipment and materials, and managed the study.
Correspondence to: Rafael Denadai, MD, Division of Coloproctology, Department of Surgery, Botucatu Medical School, University of the State of São Paulo, Distrito de Rubião Júnior s/n, 18618-000 Botucatu-SP, Brazil. denadai.rafael@hotmail.com
Telephone: +55-14-38825475 Fax: +55-14-38825475
Received: February 21, 2013
Revised: May 19, 2013
Accepted: June 1, 2013
Published online: July 27, 2013
Revised: May 19, 2013
Accepted: June 1, 2013
Published online: July 27, 2013
Core Tip
Core tip: This experimental study employed the well-established VX2 hepatic tumor rabbit model to assess the antineoplastic efficacy of intratumoral aspirin injection. Analysis of early (24 h post-treatment) and late (7 d post-treatment) effects indicated that the therapy caused early tumor destruction, as evidenced by significant necrotic areas in histopathological analysis, without late recurrence, as demonstrated by hepatic tissue regeneration and restoration of liver function biochemical parameters.